
  
    
      
        Background_NNP
        High_JJ affinity_NN humoral_NN immune_JJ responses_NNS to_TO most_JJS protein_NN
        antigens_NNS require_VBP cognate_NN interactions_NNS between_IN
        antigen-specific_JJ T_NN and_CC B_NNP cells_NNS ._. Antigen-specific_NNP T_NN cells_NNS
        encounter_VB antigen_NN presented_VBN by_IN dendritic_JJ cells_NNS that_WDT migrate_VB
        to_TO the_DT paracortical_JJ regions_NNS of_IN draining_VBG lymph_NN nodes_NNS after_IN
        initial_JJ antigen_NN contact_NN [_NN 1_CD ]_NN ._. Only_RB dendritic_JJ cells_NNS have_VBP
        the_DT capacity_NN to_TO induce_VB activation_NN in_IN resting_VBG peripheral_JJ T_NN
        cells_NNS [_NN 2_CD 3_CD ]_NN ._. Once_RB activated_VBN ,_, differentiated_JJ T_NN helper_NN
        cells_NNS contact_NN antigen-specific_JJ B_NNP cells_NNS and_CC provide_VB signals_NNS
        for_IN B_NNP cell_NN differentiation_NN via_IN CD_NNP 154_CD -_: CD_NNP 40_CD interactions_NNS ,_, as_RB
        well_RB as_IN by_IN the_DT production_NN of_IN cytokines_NNS [_NN 4_CD 5_CD 6_CD ]_NN ._.
        Consistent_NNP with_IN this_DT general_JJ understanding_NN of_IN the_DT induction_NN
        of_IN antibody_NN responses_NNS to_TO protein_NN immunogens_NNS ,_, good_JJ antibody_NN
        responses_NNS to_TO synthetic_JJ peptide-epitope_JJ constructs_NNS have_VBP been_VBN
        shown_VBN to_TO depend_VB on_IN the_DT presence_NN ,_, orientation_NN ,_, and_CC
        multiplicity_NN of_IN the_DT T_NN cell_NN epitope_NN in_IN the_DT construct_VB [_NN 7_CD 8_CD 9_CD
        10_CD 11_CD ]_NN ._. As_IN a_DT confirmation_NN of_IN this_DT finding_VBG with_IN synthetic_JJ
        epitope_NN constructs_NNS ,_, most_JJS protein_NN immunogens_NNS studied_VBN to_TO date_NN
        contain_VB multiple_JJ T_NN cell_NN epitopes_NNS ,_, for_IN example_NN [_NN 12_CD 13_CD ]_NN
        ._.
        T_NN helper_NN epitopes_NNS have_VBP become_VBN common_JJ components_NNS of_IN
        synthetic_JJ vaccine_NN constructs_NNS due_JJ to_TO their_PRP$ ability_NN to_TO
        provide_VB immunological_JJ help_NN for_IN both_DT humoral_NN and_CC
        cell-mediated_JJ responses_NNS [_NN 11_CD 14_CD 15_CD 16_CD ]_NN ._. T_NN cell_NN epitopes_NNS
        that_WDT can_MD induce_VB helper_NN activity_NN by_IN binding_VBG to_TO a_DT wide_JJ range_NN
        of_IN HLA-DR_NNP alleles_NNS have_VBP been_VBN developed_VBN by_IN a_DT number_NN of_IN
        investigators_NNS using_VBG various_JJ antigen_NN systems_NNS [_NN 17_CD 18_CD 19_CD ]_NN ._.
        T_NN cell_NN epitopes_NNS that_WDT have_VBP the_DT property_NN of_IN binding_VBG across_IN a_DT
        wide_JJ range_NN of_IN HLA-DR_NNP haplotypes_NNS are_VBP necessary_JJ for_IN the_DT
        construction_NN of_IN synthetic_JJ vaccines_NNS that_WDT would_MD be_VB useful_JJ in_IN
        the_DT human_JJ population_NN as_IN a_DT whole_NN ._. DNA-_NNP and_CC peptide-based_JJ
        vaccines_NNS have_VBP become_VBN popular_JJ due_NN to_TO the_DT comparative_JJ ease_NN of_IN
        construction_NN ,_, the_DT circumvention_NN of_IN potential_JJ safety_NN issues_NNS
        around_IN attenuated_JJ organisms_NNS ,_, and_CC for_IN their_PRP$ potentially_RB
        enhanced_JJ immunogenicity_NN compared_VBN to_TO heat-killed_JJ and_CC subunit_NN
        vaccines_NNS [_NN 20_CD 21_CD 22_CD ]_NN ._. DNA_NNP vaccines_NNS have_VBP the_DT added_VBN
        attraction_NN of_IN efficiently_RB priming_VBG both_DT humoral_NN and_CC
        cytotoxic_JJ cell_NN responses_NNS ,_, a_DT property_NN largely_RB lacking_VBG in_IN
        subunit_NN and_CC attenuated_JJ organism_NN vaccines_NNS ._. Priming_NNP of_IN
        cytotoxic_JJ cell_NN responses_NNS is_VBZ necessary_JJ for_IN the_DT design_NN of_IN
        therapeutic_JJ cancer_NN vaccines_NNS ,_, as_RB well_RB as_IN for_IN viral_JJ vaccines_NNS ._.
        Multiple_NNP antigen_NN peptide_NN vaccines_NNS can_MD also_RB be_VB designed_VBN to_TO
        contain_VB T_NN and_CC B_NNP epitope_NN regions_NNS from_IN numerous_JJ protein_NN
        antigens_NNS derived_VBN from_IN a_DT complex_JJ infectious_JJ agent_NN which_WDT
        could_MD therefore_RB confer_VB broad_JJ protection_NN without_IN the_DT
        potential_JJ dangers_NNS of_IN an_DT attenuated_JJ whole_JJ organism_NN vaccine_NN [_NN
        16_CD ]_NN ._. However_RB ,_, it_PRP is_VBZ of_IN note_NN that_IN occasionally_RB a_DT
        well-designed_JJ peptide-based_JJ vaccine_NN can_MD elicit_NN strong_JJ
        antibody_NN responses_NNS to_TO the_DT synthetic_JJ immunogen_NN that_WDT do_VBP not_RB
        confer_VB protection_NN from_IN the_DT parasite_NN to_TO which_WDT they_PRP were_VBD
        originally_RB designed_VBN [_NN 23_CD ]_NN ._. This_DT may_MD be_VB due_JJ to_TO either_CC the_DT
        induction_NN of_IN an_DT inappropriate_JJ antibody_NN isotype_NN in_IN the_DT mouse_NN
        strain_NN used_VBD ,_, or_CC to_TO an_DT inadequate_JJ overall_JJ response_NN ._.
        While_IN subunit_NN vaccines_NNS have_VBP their_PRP$ inherent_JJ shortcomings_NNS ,_,
        they_PRP carry_VBP the_DT added_VBN benefit_NN of_IN potentially_RB inducing_VBG
        complex_JJ antibody_NN responses_NNS to_TO multiple_JJ sites_NNS on_IN the_DT whole_JJ
        protein_NN immunogen_NN ._. Subunit_NNP vaccines_NNS are_VBP of_IN interest_NN in_IN the_DT
        prevention_NN of_IN parasite_NN infection_NN [_NN 24_CD ]_NN and_CC for_IN a_DT variety_NN
        of_IN infectious_JJ diseases_NNS [_NN 25_CD ]_NN ._. An_DT ideal_JJ subunit_NN vaccine_NN
        for_IN the_DT induction_NN of_IN protective_JJ antibody_NN responses_NNS would_MD be_VB
        a_DT protein_NN from_IN the_DT disease-causing_JJ organism_NN that_WDT was_VBD
        minimally_RB modified_VBN from_IN its_PRP$ original_JJ structure_NN to_TO retain_VB a_DT
        variety_NN of_IN potential_JJ B_NNP cell_NN epitopes_NNS ._. In_IN addition_NN ,_, the_DT
        modified_VBN subunit_NN vaccine_NN would_MD be_VB designed_VBN to_TO be_VB highly_RB
        immunogenic_JJ by_IN the_DT addition_NN of_IN promiscuous_JJ T_NN cell_NN epitopes_NNS ._.
        To_TO this_DT end_NN ,_, we_PRP have_VBP characterized_VBN the_DT immune_JJ response_NN of_IN
        partially_RB outbred_JJ Hartley_NNP strain_NN guinea_NN pigs_NNS to_TO two_CD related_VBN
        bacterial_JJ proteases_NNS ._. The_DT two_CD bacterial_JJ enzymes_NNS studied_VBN
        represent_VB important_JJ industrial_JJ enzymes_NNS used_VBN in_IN a_DT number_NN of_IN
        applications_NNS ,_, including_VBG serving_VBG as_IN an_DT additive_JJ for_IN laundry_NN
        products_NNS ,_, and_CC animal_NN feed_NN processing_NN ._. These_DT enzymes_NNS have_VBP
        been_VBN well_RB characterized_VBN as_IN to_TO their_PRP$ activity_NN and_CC
        specificity_NN by_IN us_PRP and_CC by_IN others_NNS [_NN 26_CD 27_CD ]_NN ._. While_IN these_DT two_CD
        proteins_NNS are_VBP approximately_RB 60_CD %_NN homologous_RB at_IN the_DT amino_JJ acid_NN
        sequence_NN [_NN 26_CD ]_NN ,_, one_CD of_IN the_DT proteases_NNS was_VBD significantly_RB
        less_RBR immunogenic_JJ than_IN the_DT other_JJ ._. Reduced_NNP immunogenicity_NN was_VBD
        characterized_VBN as_RB significantly_RB lower_JJR titers_NNS of_IN
        antigen-specific_JJ IgG_NNP when_WRB animals_NNS were_VBD immunized_JJ with_IN the_DT
        same_JJ amount_NN of_IN the_DT enzymes_NNS ._. We_PRP determined_VBD the_DT T_NN cell_NN
        epitopes_NNS in_IN both_DT of_IN the_DT proteases_NNS using_VBG 15_CD -_: mer_NN peptides_NNS and_CC
        splenocytes_NNS from_IN immunized_JJ animals_NNS ._. In_IN order_NN to_TO be_VB
        classified_VBN as_IN an_DT epitope_NN ,_, the_DT average_JJ proliferative_JJ
        response_NN to_TO a_DT peptide_NN had_VBD to_TO reach_VB a_DT stimulation_NN index_NN of_IN
        3_CD ._. 0_CD ._. Two_CD regions_NNS met_VBD our_PRP$ criteria_NNS as_IN epitopes_NNS in_IN the_DT
        immunogenic_JJ protease_NN ._. We_PRP tested_VBD a_DT total_NN of_IN 20_CD guinea_NN pigs_NNS
        and_CC found_VBD no_DT epitope_NN regions_NNS in_IN the_DT less_RBR immunogenic_JJ
        protease_NN ._. A_DT sequence_NN comparison_NN of_IN the_DT enzymes_NNS in_IN the_DT T_NN
        cell_NN epitope_NN regions_NNS revealed_VBD that_IN a_DT single_JJ amino_JJ acid_NN
        change_NN could_MD confer_VB a_DT T_NN cell_NN epitope_NN onto_IN the_DT
        less-immunogenic_JJ protease_NN ._. This_DT variant_NN was_VBD constructed_VBN ,_,
        and_CC was_VBD found_VBN to_TO be_VB a_DT functional_JJ and_CC stable_JJ protease_NN ._.
        Immunization_NNP of_IN Hartley_NNP strain_NN guinea_NN pigs_NNS showed_VBD that_IN this_DT
        single_JJ amino_JJ acid_NN change_NN created_VBD a_DT T_NN cell_NN epitope_NN where_WRB
        there_EX was_VBD no_DT detectable_JJ epitope_NN before_RB ,_, and_CC the_DT presence_NN of_IN
        this_DT epitope_NN correlates_NNS with_IN an_DT improved_VBN immunogenicity_NN in_IN
        the_DT variant_NN ._. Finally_RB ,_, we_PRP show_VBP that_IN the_DT variant_NN induces_VBZ
        broadly_RB cross-reactive_JJ IgG_NNP antibodies_NNS ,_, and_CC that_IN priming_VBG of_IN
        animals_NNS with_IN the_DT variant_NN protein_NN results_NNS in_IN higher_JJR titers_NNS
        of_IN antigen-specific_JJ antibody_NN upon_IN subsequent_JJ immunization_NN
        with_IN the_DT parent_NN enzyme_NN ._.
      
      
        Results_NNS
        
          IgG_NNP antibody_NN titers_NNS from_IN B_NNP ._. lentussubtilisin_NN and_CC
          BPN_NNP '_POS Y_NNP 217_CD L_NNP guinea_NN pig_NN immunizations_NNS
          Female_NNP Hartley_NNP strain_NN guinea_NN pigs_NNS were_VBD immunized_JJ with_IN
          two_CD related_VBN bacterial_JJ proteases_NNS ,_, 
          B_NNP ._. lentus_JJ subtilisin_NN and_CC BPN_NNP '_POS
          Y_NNP 217_CD L_NNP ._. These_DT two_CD bacterial_JJ enzymes_NNS share_VBP 60_CD %_NN homology_NN at_IN
          the_DT amino_JJ acid_NN level_NN ._. They_PRP are_VBP also_RB comparable_JJ in_IN their_PRP$
          proteolytic_JJ activity_NN and_CC specificity_NN [_NN 26_CD 27_CD ]_NN ._. Animals_NNS
          were_VBD immunized_JJ every_DT two_CD weeks_NNS with_IN a_DT 20_CD ug_NN dose_NN of_IN
          enzyme_NN in_IN adjuvant_NN ._. Serum_NNP samples_NNS were_VBD drawn_VBN prior_RB to_TO
          each_DT immunization_NN over_IN a_DT ten-week_JJ period_NN ._. Serum_NNP samples_NNS
          were_VBD tested_VBN for_IN antigen-specific_JJ IgG_NNP antibodies_NNS by_IN ELISA_NNP ._.
          Titers_NNP were_VBD calculated_VBN for_IN each_DT animal_NN 's_POS antibody_NN
          response_NN ._. Averages_NNP for_IN four_CD animals_NNS are_VBP presented_VBN in_IN
          Figure_NN 1_CD ._. The_DT titers_NNS over_IN time_NN are_VBP presented_VBN as_IN serum_NN
          dilution_NN (_( B_NNP )_) and_CC as_IN Log_NNP 2_CD titers_NNS (_( A_DT )_) ._. Immunization_NNP with_IN 
          B_NNP ._. lentus_JJ subtilisin_NN induced_VBN higher_JJR
          titers_NNS of_IN antigen-specific_JJ IgG_NNP than_IN BPN_NNP '_POS Y_NNP 217_CD L_NNP after_IN 4_CD
          weeks_NNS ._. The_DT response_NN to_TO 
          B_NNP ._. lentus_JJ subtilisin_NN reached_VBD
          maximal_NN levels_NNS by_IN about_IN 6_CD weeks_NNS ._. At_IN the_DT 6_CD to_TO 10_CD week_NN time_NN
          points_NNS ,_, titers_NNS leveled_VBN off_IN and_CC the_DT average_JJ titers_NNS induced_VBN
          by_IN immunizations_NNS with_IN 
          B_NNP ._. lentus_JJ subtilisin_NN were_VBD about_IN 10_CD
          fold_VB higher_JJR than_IN BPN_NNP '_POS Y_NNP 217_CD L_NNP ._. 
          B_NNP ._. lentus_JJ subtilisin_NN remained_VBD more_RBR
          immunogenic_JJ at_IN doses_NNS from_IN 1_CD to_TO 20_CD μg_NN ._. (_( not_RB shown_VBN )_) ._.
          Overall_RB maximum_NN titer_NN levels_NNS vary_VBP ,_, but_CC the_DT difference_NN in_IN
          immunogenicity_NN between_IN 
          B_NNP ._. lentus_JJ subtilisin_NN and_CC BPN_NNP '_POS Y_NNP 217_CD L_NNP
          has_VBZ been_VBN seen_VBN in_IN three_CD separate_JJ guinea_NN pig_NN studies_NNS ._. This_DT
          difference_NN in_IN immunogenicity_NN has_VBZ been_VBN noted_VBN by_IN others_NNS
          using_VBG an_DT intratracheal_NN method_NN of_IN immunization_NN [_NN 28_CD 29_CD ]_NN
          ._.
        
        
          T_NN cell_NN epitope_NN mapping_NN of_IN B_NNP ._. lentussubtilisin_NN and_CC
          BPN_NNP '_POS Y_NNP 217_CD L_NNP
          Splenocytes_NNP from_IN immunized_JJ guinea_NN pigs_NNS were_VBD used_VBN to_TO
          determine_VB the_DT position_NN of_IN T_NN cell_NN epitopes_NNS in_IN 
          B_NNP ._. lentus_JJ subtilisin_NN and_CC BPN_NNP '_POS
          Y_NNP 217_CD L_NNP ._. 10_CD animals_NNS were_VBD tested_VBN for_IN each_DT immunogen_NN ._. 15_CD -_: mer_NN
          peptides_NNS offset_VBN by_IN 3_CD amino_JJ acids_NNS were_VBD used_VBN at_IN 5_CD μM_NN ,_, and_CC
          were_VBD tested_VBN at_IN least_JJS in_IN duplicate_VB for_IN each_DT immunized_JJ
          animal_NN ._. Peptides_NNP eliciting_VBG a_DT 3_CD -_: fold_VB or_CC higher_JJR average_JJ
          proliferative_JJ response_NN over_IN the_DT background_NN response_NN were_VBD
          considered_VBN T_NN cell_NN epitopes_NNS ._. These_DT epitopes_NNS are_VBP shown_VBN in_IN
          bold_JJ in_IN Figure_NN 2_CD ._. Two_CD T_NN cell_NN epitopes_NNS were_VBD found_VBN in_IN 5_CD of_IN
          the_DT 10_CD guinea_NN pigs_NNS immunized_JJ with_IN 
          B_NNP ._. lentus_JJ subtilisin_NN ,_, but_CC none_NN
          meeting_VBG the_DT criteria_NNS of_IN a_DT three-fold_JJ increase_NN in_IN
          proliferation_NN over_IN the_DT background_NN were_VBD found_VBN in_IN the_DT 10_CD
          animals_NNS immunized_JJ with_IN BPN_NNP '_POS Y_NNP 217_CD L_NNP in_IN this_DT experiment_NN (_( p_NN =_SYM
          0_CD ._. 01_CD ;_: non-parametric_JJ Student_NNP '_POS t-test_JJ )_) ._. Notably_RB ,_, the_DT first_JJ
          
          B_NNP ._. lentus_JJ subtilisin_NN epitope_NN has_VBZ an_DT
          analogous_JJ region_NN in_IN BPN_NNP '_POS Y_NNP 217_CD L_NNP ._. only_RB the_DT first_JJ amino_JJ acid_NN
          is_VBZ different_JJ ._. It_PRP was_VBD hypothesized_VBN that_IN if_IN the_DT first_JJ
          valine_NN in_IN the_DT analogous_JJ BPN_NNP '_POS Y_NNP 217_CD L_NNP sequence_NN was_VBD changed_VBN
          to_TO an_DT isoleucine_NN ,_, a_DT T_NN cell_NN epitope_NN analogous_JJ to_TO the_DT one_CD
          found_VBD in_IN 
          B_NNP ._. lentus_JJ subtilisin_NN would_MD be_VB
          created_VBN ._. A_DT modified_VBN BPN_NNP '_POS Y_NNP 217_CD L_NNP V_NNP 72_CD I_PRP enzyme_NN (_( GP_NNP 002_CD )_) was_VBD
          prepared_VBN with_IN this_DT single_JJ amino_JJ acid_NN change_NN (_( Figure_NN
          3_LS )_) ._.
        
        
          Enzyme_NNP activity_NN and_CC stability_NN
          Enzymatic_NNP activity_NN has_VBZ been_VBN implicated_VBN as_IN a_DT source_NN of_IN
          the_DT allergenic_JJ property_NN of_IN Der_NNP p_NN 1_CD ,_, the_DT major_JJ dust_NN mite_NN
          allergen_NN [_NN 30_CD 31_CD 32_CD ]_NN ._. In_IN order_NN to_TO account_VB for_IN this_DT
          variable_NN ,_, the_DT enzymatic_JJ activity_NN of_IN the_DT variant_NN protease_NN
          GP_NNP 002_CD was_VBD compared_VBN BPN_NNP '_POS Y_NNP 217_CD L_NNP ._. Proteolytic_NNP activity_NN was_VBD
          determined_VBN in_IN a_DT standard_JJ sAAPF_NN hydrolysis_NNS assay_NN ._. The_DT
          activity_NN of_IN GP_NNP 002_CD was_VBD found_VBN to_TO be_VB approximately_RB 80_CD %_NN of_IN
          the_DT parent_JJ BPN_NNP '_POS Y_NNP 217_CD L_NNP enzyme_NN (_( Figure_NN 4_LS )_) ._. Another_DT factor_NN
          that_WDT could_MD influence_VB the_DT immunogenicity_NN of_IN a_DT proteolytic_JJ
          enzyme_NN is_VBZ the_DT relative_JJ stability_NN of_IN the_DT protease_NN ._. If_IN the_DT
          protease_NN remains_VBZ active_JJ for_IN a_DT longer_JJR period_NN of_IN time_NN ,_, any_DT
          effects_NNS of_IN the_DT activity_NN would_MD be_VB comparatively_RB magnified_VBN ._.
          The_DT half-lives_JJ of_IN both_DT enzymes_NNS were_VBD tested_VBN at_IN 37_CD °_NN C_NNP over_IN a_DT
          74_CD -_: hour_NN time_NN period_NN to_TO assess_VB relative_JJ stability_NN ._. The_DT
          assay_NN was_VBD performed_VBN at_IN physiologic_JJ pH_NN =_SYM 7_CD ._. 3_CD ._. At_IN various_JJ
          time_NN points_NNS ,_, the_DT proteolytic_JJ activity_NN remaining_VBG in_IN the_DT
          samples_NNS were_VBD tested_VBN ._. At_IN 37_CD degrees_NNS and_CC a_DT pH_NN of_IN 7_CD ._. 3_CD ,_, BPN_NNP '_POS
          Y_NNP 217_CD L_NNP has_VBZ a_DT half-life_NN fifty-five_JJ hours_NNS longer_RBR than_IN GP_NNP 002_CD ._.
          These_DT results_NNS indicate_VBP that_IN the_DT two_CD enzymes_NNS have_VBP
          comparable_JJ stability_NN and_CC efficacy_NN ._. Comparable_JJ enzymatic_JJ
          activity_NN and_CC stability_NN suggest_VBP that_IN the_DT variant_NN molecule_NN
          has_VBZ a_DT similar_JJ tertiary_JJ configuration_NN as_IN the_DT parent_NN ._.
        
        
          T-_NNP cell_NN epitope_NN mapping_NN BPN_NNP '_POS Y_NNP 217_CD L_NNP versus_CC
          GP_NNP 002_CD
          Hartley_NNP strain_NN guinea_NN pigs_NNS were_VBD immunized_JJ with_IN 5_CD μg_NN
          per_IN dose_NN of_IN either_DT BPN_NNP '_POS Y_NNP 217_CD L_NNP or_CC GP_NNP 002_CD every_DT two_CD weeks_NNS ._.
          After_IN 6_CD weeks_NNS epitope_NN mapping_NN was_VBD performed_VBN as_IN described_VBN
          using_VBG the_DT BPN_NNP '_POS Y_NNP 217_CD L_NNP 15_CD -_: mer_NN PepSet_NNP and_CC splenocytes_NNS from_IN
          the_DT primed_VBN animals_NNS (_( Figure_NN 5_LS )_) ._. In_IN addition_NN ,_, proliferative_JJ
          responses_NNS to_TO the_DT intact_JJ inactivated_JJ BPN_NNP '_POS Y_NNP 217_CD L_NNP enzyme_NN
          were_VBD tested_VBN ._. Immunization_NNP with_IN GP_NNP 002_CD resulted_VBD in_IN an_DT
          increased_VBN proliferative_JJ response_NN to_TO whole_JJ protein_NN
          BPN_NNP '_POS Y_NNP 217_CD L_NNP ._. The_DT average_JJ stimulation_NN index_NN (_( proliferative_JJ
          response_NN to_TO enzyme_NN /_NN proliferation_NN in_IN control_NN cultures_NNS )_) to_TO
          20_CD ug_NN of_IN whole_JJ protein_NN was_VBD 23_CD ,_, versus_CC an_DT average_JJ
          stimulation_NN index_NN of_IN 11_CD for_IN the_DT BPN_NNP '_POS Y_NNP 217_CD L-_NNP immunized_JJ
          splenocytes_NNS ._. Epitope_NNP mapping_NN with_IN splenocytes_NNS from_IN BPN_NNP '_POS
          Y_NNP 217_CD L_NNP immunized_JJ guinea_NN pigs_NNS revealed_VBD no_DT epitope_NN regions_NNS
          with_IN an_DT average_JJ stimulation_NN index_NN of_IN 3_CD ._. 0_CD in_IN any_DT of_IN the_DT
          animals_NNS tested_VBN (_( n_NN =_SYM 5_LS )_) ._. This_DT is_VBZ consistent_JJ with_IN our_PRP$
          previous_JJ results_NNS for_IN this_DT enzyme_NN ,_, using_VBG splenocytes_NNS from_IN
          animals_NNS immunized_JJ with_IN 20_CD ug_NN per_IN dose_NN of_IN enzyme_NN every_DT two_CD
          weeks_NNS for_IN 10_CD weeks_NNS ._. Four_CD out_IN of_IN five_CD of_IN the_DT GP_NNP 002_CD
          immunized_JJ animals_NNS responded_VBD with_IN stimulation_NN indices_NNS of_IN
          greater_JJR than_IN 3_CD ._. 0_CD to_TO the_DT modified_VBN epitope_NN region_NN in_IN BPN_NNP '_POS
          Y_NNP 217_CD L_NNP (_( peptide_NN #_# 25_CD )_) ._. The_DT average_JJ response_NN to_TO this_DT peptide_NN
          was_VBD approximately_RB 4_CD ._. 0_CD ._. Peptide_NNP #_# 25_CD is_VBZ offset_VBN from_IN the_DT T_NN
          cell_NN epitope_NN described_VBD in_IN 
          B_NNP ._. lentus_JJ by_IN 2_CD amino_JJ acids_NNS ._. This_DT is_VBZ
          a_DT result_NN of_IN creating_VBG linear_JJ 15_CD -_: mers_NNS from_IN the_DT two_CD
          sequences_NNS where_WRB there_EX is_VBZ a_DT 2_CD amino_JJ acid_NN contraction_NN in_IN 
          B_NNP ._. lentus_JJ subtilisin_NN as_IN compared_VBN to_TO
          the_DT BPN_NNP '_POS Y_NNP 217_CD L_NNP sequence_NN ._. Primed_NNP splenocytes_NNS from_IN guinea_NN
          pigs_NNS also_RB respond_VBP to_TO peptide_NN #_# 24_CD that_WDT is_VBZ 3_CD amino_JJ acids_NNS
          offset_VBN towards_IN to_TO N-_NNP terminus_JJ ,_, and_CC subsequently_RB overlaps_NNS
          with_IN the_DT T_NN cell_NN epitope_NN region_NN ._. The_DT creation_NN of_IN a_DT T_NN cell_NN
          epitope_NN in_IN BPN_NNP '_POS Y_NNP 217_CD L_NNP also_RB resulted_VBD in_IN the_DT display_NN of_IN a_DT
          complex_JJ set_NN of_IN weak_JJ epitopes_NNS in_IN the_DT molecule_NN ._. Peptides_NNP
          #_# 25_CD and_CC #_# 75_CD induced_VBN average_JJ responses_NNS over_IN the_DT 5_CD animals_NNS
          that_WDT reached_VBD an_DT S_NNP ._. I_PRP ._. of_IN approximately_RB 3_CD ._. 0_CD ._. Five_CD peptide_NN
          regions_NNS induced_VBD average_JJ responses_NNS of_IN approximately_RB 2_CD ._. 5_CD ._.
          Therefore_RB ,_, creation_NN of_IN a_DT strong_JJ T_NN cell_NN epitope_NN in_IN this_DT
          protein_NN initiates_NNS an_DT immune_JJ response_NN that_WDT leads_VBZ to_TO the_DT
          diversification_NN of_IN T_NN cell_NN responses_NNS to_TO other_JJ regions_NNS of_IN
          the_DT molecule_NN ._.
        
        
          Antibody_NNP titers_NNS with_IN BPN_NNP '_POS Y_NNP 217_CD L_NNP and_CC GP_NNP 002_CD
          In_IN order_NN to_TO test_VB whether_IN the_DT modified_VBN enzyme_NN could_MD
          induce_VB higher_JJR titers_NNS of_IN antigen-specific_JJ IgG_NNP now_RB that_IN it_PRP
          carried_VBD a_DT strong_JJ T_NN cell_NN epitope_NN ,_, guinea_NN pigs_NNS were_VBD
          immunized_JJ with_IN increasing_VBG doses_NNS of_IN BPN_NNP '_POS Y_NNP 217_CD L_NNP or_CC GP_NNP 002_CD ._.
          Serum_NNP samples_NNS were_VBD taken_VBN every_DT two_CD weeks_NNS and_CC titers_NNS were_VBD
          calculated_VBN ._. Average_JJ titers_NNS for_IN four_CD animals_NNS per_IN group_NN are_VBP
          shown_VBN in_IN Figure_NN 6_CD ._. Immunization_NNP with_IN the_DT modified_VBN enzyme_NN
          resulted_VBD in_IN higher_JJR titers_NNS of_IN antigen-specific_JJ IgG_NNP at_IN
          early_JJ time_NN points_NNS in_IN the_DT immunization_NN protocol_NN (_( Figure_NN
          6_CD a_DT )_) ._. At_IN later_JJ points_VBZ during_IN the_DT immunization_NN protocol_NN ,_,
          lower_JJR doses_NNS of_IN the_DT variant_NN induced_VBN higher_JJR titers_NNS than_IN the_DT
          parent_NN (_( Figure_NN 6_CD b_SYM ,_, c_SYM ,_, d_SYM )_) ._. At_IN four_CD weeks_NNS ,_, the_DT 20_CD ug_NN dose_NN
          GP_NNP 002_CD induced_VBD an_DT average_JJ serum_NN dilution_NN titer_NN of_IN 5_CD ,_, 000_CD
          versus_CC no_DT detectable_JJ IgG_NNP in_IN the_DT BPN_NNP '_POS Y_NNP 217_CD L_NNP immunized_JJ
          animals_NNS ._. This_DT difference_NN between_IN GP_NNP 002_CD and_CC BPN_NNP '_POS Y_NNP 217_CD L_NNP has_VBZ
          a_DT p_NN value_NN of_IN 0_CD ._. 03_CD when_WRB calculated_VBN using_VBG a_DT two-tailed_JJ ,_,
          non-parametric_JJ Student_NNP 's_POS t-test_JJ ._. By_IN ten_CD weeks_NNS ,_, the_DT
          difference_NN is_VBZ no_RB longer_RB detected_VBD at_IN the_DT 5_CD and_CC 20_CD μg_NN doses_NNS
          but_CC there_EX is_VBZ still_RB a_DT ten-fold_JJ difference_NN in_IN titers_NNS at_IN the_DT
          lowest_JJS dose_NN ._.
        
        
          Linear_NNP B_NNP Cell_NNP Epitopes_NNP BPN_NNP '_POS Y_NNP 217_CD L_NNP v_NN ._. GP_NNP 002_CD
          A_DT potential_JJ explanation_NN for_IN the_DT increase_NN in_IN antibody_NN
          titers_NNS is_VBZ that_IN the_DT modification_NN in_IN GP_NNP 002_CD results_NNS in_IN a_DT
          conformationally_RB distinct_JJ molecule_NN with_IN unique_JJ surface_NN
          regions_NNS ,_, thereby_RB increasing_VBG the_DT total_JJ number_NN of_IN antibody_NN
          binding_JJ sites_NNS ._. Guinea_NNP pig_NN serum_NN samples_NNS from_IN animals_NNS
          immunized_JJ with_IN 5_CD μg_NN of_IN enzyme_NN were_VBD used_VBN to_TO determine_VB the_DT
          position_NN of_IN linear_JJ B-_NNP cell_NN epitopes_NNS in_IN BPN_NNP '_POS Y_NNP 217_CD L_NNP (_( Figure_NN
          7_CD )_) ._. The_DT serum_NN samples_NNS were_VBD drawn_VBN at_IN 8_CD weeks_NNS ,_, and_CC whole_JJ
          protein_NN titers_NNS are_VBP shown_VBN in_IN Figure_NN 6_CD ._. Serum_NNP samples_NNS from_IN
          four_CD animals_NNS immunized_JJ with_IN BPN_NNP '_POS Y_NNP 217_CD L_NNP and_CC four_CD animals_NNS
          immunized_JJ with_IN GP_NNP 002_CD were_VBD tested_VBN on_IN biotinylated_JJ 15_CD -_: mer_NN
          peptides_NNS (_( offset_VBN by_IN 5_CD amino_JJ acids_NNS )_) ._. Serum_NNP was_VBD diluted_VBN
          1_CD :_: 1000_CD for_IN all_DT tests_NNS ._. Guinea_NNP pig_NN IgG_NNP was_VBD detected_VBN with_IN
          HRP-conjugated_NNP anti-_NN IgG_NNP ._. The_DT average_JJ optical_JJ densities_NNS
          for_IN each_DT peptide_NN were_VBD divided_VBN by_IN the_DT background_NN ._. The_DT
          average_JJ result_NN for_IN each_DT peptide_NN is_VBZ shown_VBN ._. The_DT linear_JJ
          B-_NNP cell_NN epitope_NN regions_NNS recognized_VBN by_IN both_DT polyclonal_NN
          serum_NN samples_NNS are_VBP similar_JJ ._. The_DT amino_JJ acid_NN modification_NN in_IN
          GP_NNP 002_CD would_MD be_VB in_IN the_DT region_NN of_IN peptides_NNS #_# 13_CD to_TO #_# 16_CD ._. If_IN
          the_DT amino_JJ acid_NN modification_NN produced_VBD a_DT B_NNP cell_NN epitope_NN at_IN
          this_DT site_NN ,_, it_PRP does_VBZ not_RB cross-react_JJ onto_IN the_DT unmodified_JJ
          peptide_NN regions_NNS tested_VBN here_RB ._. The_DT regions_NNS of_IN the_DT BPN_NNP '_POS
          Y_NNP 217_CD L_NNP molecule_NN detected_VBD in_IN this_DT assay_NN are_VBP predicted_VBN
          external_JJ loops_NNS (_( Dr_NNP ._. Richard_NNP Bott_NNP ,_, Genencor_NNP International_NNP ,_,
          personal_JJ communication_NN )_) ._. The_DT major_JJ regions_NNS recognized_VBN ,_,
          peptides_NNS #_# 3_CD and_CC 4_CD ,_, #_# 17_CD and_CC 18_CD ,_, and_CC #_# 46_CD and_CC 47_CD are_VBP
          equivalently_RB recognized_VBN by_IN both_DT serum_NN sets_NNS ._. Of_IN the_DT 29_CD
          regions_NNS of_IN the_DT molecule_NN showing_VBG an_DT average_JJ two-fold_JJ
          increase_NN in_IN IgG_NNP binding_VBG over_IN the_DT background_NN ,_, 17_CD of_IN these_DT
          regions_NNS are_VBP detected_VBN more_RBR strongly_RB by_IN the_DT GP_NNP 002_CD sera_NN ._. 5_LS
          peptide_NN regions_NNS are_VBP uniquely_RB detected_VBN by_IN the_DT BPN_NNP '_POS Y_NNP 217_CD L_NNP
          serum_NN ,_, and_CC 7_CD are_VBP uniquely_RB recognized_VBN by_IN the_DT GP_NNP 002_CD serum_NN ._.
          There_EX is_VBZ a_DT shift_NN in_IN one_CD epitope_NN region_NN from_IN peptides_NNS
          #_# 38_CD -_: 43_CD where_WRB the_DT GP_NNP 002_CD antibody_NN epitope_NN runs_VBZ from_IN peptide_NN
          38_CD to_TO peptide_NN 41_CD ,_, and_CC BPN_NNP '_POS Y_NNP 217_CD L_NNP 's_POS runs_NNS from_IN peptide_NN 40_CD
          to_TO peptide_NN 43_CD ._. This_DT 10_CD amino_JJ acid_NN shift_NN forward_RB indicates_VBZ
          a_DT slight_JJ difference_NN in_IN protein_NN folding_NN ._. This_DT difference_NN
          has_VBZ little_RB apparent_JJ effect_NN on_IN the_DT other_JJ antibody_NN epitopes_NNS
          delineated_JJ by_IN this_DT assay_NN ._. This_DT assay_NN demonstrates_VBZ that_IN
          GP_NNP 002_CD -_: specific_JJ IgG_NNP antibodies_NNS readily_RB cross-react_JJ with_IN
          BPN_NNP '_POS Y_NNP 217_CD L_NNP linear_JJ antibody_NN epitopes_NNS ._.
        
        
          BPN_NNP '_POS Y_NNP 217_CD L_NNP and_CC GP_NNP 002_CD Priming_NNP Immunizations_NNP
          It_PRP was_VBD of_IN interest_NN to_TO determine_VB whether_IN increased_VBN
          titers_NNS of_IN IgG_NNP antibodies_NNS to_TO BPN_NNP '_POS Y_NNP 217_CD L_NNP could_MD be_VB induced_VBN
          by_IN priming_VBG animals_NNS with_IN the_DT T_NN cell_NN epitope-containing_JJ
          variant_NN ._. Four_CD sets_NNS of_IN four_CD guinea_NN pigs_NNS were_VBD immunized_JJ
          with_IN 5_CD μg_NN of_IN enzyme_NN over_IN a_DT six-week_JJ period_NN in_IN series_NN ._. The_DT
          animals_NNS were_VBD immunized_JJ three_CD times_NNS ,_, once_RB every_DT two_CD weeks_NNS ._.
          This_DT protocol_NN was_VBD chosen_VBN to_TO correspond_VB with_IN the_DT titer_NN
          data_NN presented_VBN in_IN Figure_NN 6_CD ._. Group_NNP A_DT was_VBD immunized_JJ three_CD
          times_NNS with_IN BPN_NNP '_POS Y_NNP 217_CD L_NNP ,_, Group_NNP B_NNP was_VBD immunized_JJ first_NN with_IN
          the_DT GP_NNP 002_CD ,_, and_CC then_RB twice_RB with_IN BPN_NNP '_POS Y_NNP 217_CD L_NNP ._. Group_NNP C_NNP was_VBD
          immunized_JJ the_DT first_JJ two_CD times_NNS with_IN the_DT GP_NNP 002_CD ,_, and_CC the_DT
          third_JJ time_NN with_IN BPN_NNP '_POS Y_NNP 217_CD L_NNP ._.
          Finally_RB ,_, Group_NNP D_NNP was_VBD immunized_JJ all_DT three_CD times_NNS with_IN
          GP_NNP 002_CD ._. Two_CD weeks_NNS after_IN the_DT last_JJ immunization_NN serum_NN
          samples_NNS were_VBD taken_VBN and_CC ELISAs_NNP were_VBD performed_VBN to_TO compare_VB
          titers_NNS ._. All_DT ELISAs_NNP were_VBD performed_VBN using_VBG the_DT parent_NN
          enzyme_NN ,_, BPN_NNP '_POS Y_NNP 217_CD L_NNP ,_, as_IN a_DT plate_NN coating_NN reagent_NN ._. Results_NNS
          clearly_RB show_VBP once_RB again_RB that_DT immunization_NN with_IN GP_NNP 002_CD
          induces_VBZ over_IN 10_CD -_: fold_VB higher_JJR levels_NNS of_IN antigen-specific_JJ
          IgG_NNP than_IN the_DT unmodified_JJ parent_NN enzyme_NN (_( Figure_NN 8_CD )_) ._. The_DT
          difference_NN between_IN group_NN A_DT and_CC D_NNP was_VBD highly_RB significant_JJ
          (_( p_NN <_NN 0_CD ._. 01_CD )_) ._. In_IN addition_NN ,_, a_DT single_JJ immunization_NN with_IN
          the_DT T_NN cell_NN epitope_NN modified_VBN variant_NN GP_NNP 002_CD is_VBZ sufficient_JJ
          to_TO induce_VB higher_JJR levels_NNS of_IN parent-enzyme-specific_JJ IgG_NNP
          after_IN subsequent_JJ immunizations_NNS with_IN the_DT unmodified_JJ parent_NN
          enzyme_NN ._. While_IN the_DT average_JJ titer_NN increased_VBD by_IN
          approximately_RB two-fold_JJ ,_, the_DT difference_NN between_IN group_NN A_DT
          and_CC B_NNP was_VBD not_RB statistically_RB significant_JJ ._. Each_DT group_NN
          contained_VBD only_RB four_CD animals_NNS ,_, with_IN appreciable_JJ scatter_NN in_IN
          the_DT individual_JJ responses_NNS ._. Two_CD immunizations_NNS with_IN GP_NNP 002_CD
          prior_RB to_TO immunizing_VBG with_IN the_DT parent_NN enzyme_NN did_VBD not_RB
          improve_VB the_DT titers_NNS as_IN compared_VBN to_TO a_DT single_JJ priming_VBG
          immunization_NN with_IN GP_NNP 002_CD ._. This_DT result_NN suggests_VBZ that_IN
          priming_VBG with_IN the_DT variant_NN enzyme_NN can_MD induce_VB higher_JJR levels_NNS
          of_IN cross-reactive_JJ IgG_NNP antibodies_NNS than_IN immunization_NN with_IN
          the_DT unmodified_JJ variant_NN alone_RB ._. This_DT experiment_NN also_RB
          confirms_VBZ that_IN GP_NNP 002_CD immunized_JJ animals_NNS produce_VBP high_JJ titers_NNS
          of_IN IgG_NNP that_IN cross-react_JJ on_IN the_DT whole_JJ BPN_NNP '_POS Y_NNP 217_CD L_NNP
          molecule_NN ._.
        
      
      
        Discussion_NNP
        We_PRP have_VBP shown_VBN that_IN a_DT single_JJ conservative_JJ amino_JJ acid_NN
        change_NN in_IN a_DT bacterial_JJ subtilisin_NN enzyme_NN can_MD create_VB a_DT strong_JJ
        T_NN cell_NN epitope_NN in_IN our_PRP$ guinea_NN pig_NN model_NN ._. Immunization_NNP of_IN
        guinea_NN pigs_NNS with_IN this_DT modified_JJ variant_NN results_NNS in_IN an_DT
        improved_VBN cross-reactive_JJ immune_JJ response_NN to_TO the_DT unmodified_JJ
        parent_NN enzyme_NN in_IN both_DT antigen-specific_JJ IgG_NNP antibody_NN
        production_NN and_CC T_NN cell_NN proliferative_JJ responses_NNS ._. The_DT improved_VBN
        immunogenicity_NN of_IN the_DT variant_NN was_VBD not_RB related_VBN to_TO changes_NNS in_IN
        the_DT proteolytic_JJ capacity_NN of_IN the_DT enzyme_NN ,_, because_IN the_DT variant_NN
        exhibited_VBN 80_CD %_NN of_IN the_DT activity_NN of_IN the_DT parent_NN enzyme_NN ._. The_DT
        introduction_NN of_IN a_DT single_JJ T_NN cell_NN epitope_NN apparently_RB allowed_VBD
        for_IN the_DT diversification_NN of_IN T_NN cell_NN responses_NNS to_TO the_DT protein_NN
        because_IN multiple_JJ epitopes_NNS were_VBD found_VBN in_IN the_DT BPN_NNP '_POS Y_NNP 217_CD L_NNP
        sequence_NN after_IN immunization_NN of_IN animals_NNS with_IN the_DT variant_NN
        (_( Figure_NN 5_LS )_) ._. An_DT increase_NN in_IN the_DT complexity_NN of_IN the_DT T_NN cell_NN
        response_NN is_VBZ consistent_JJ with_IN an_DT increase_NN in_IN overall_JJ antibody_NN
        titer_NN to_TO the_DT enzyme_NN ,_, as_IN more_JJR T_NN cell_NN helper_NN activity_NN is_VBZ
        potentially_RB available_JJ ._. The_DT antibody_NN responses_NNS to_TO the_DT
        variant_NN and_CC parent_NN enzymes_NNS were_VBD shown_VBN to_TO be_VB largely_RB
        overlapping_VBG ,_, indicating_VBG that_IN the_DT increase_NN in_IN the_DT antibody_NN
        titers_NNS seen_VBN were_VBD not_RB due_JJ to_TO the_DT addition_NN of_IN a_DT novel_NN
        structure_NN capable_JJ of_IN being_VBG recognized_VBN by_IN unique_JJ antibody_NN
        specificities_NNS ._. This_DT is_VBZ shown_VBN by_IN the_DT last_JJ experiment_NN where_WRB
        priming_VBG with_IN the_DT variant_NN enzyme_NN increased_VBD antibody_NN titers_NNS
        to_TO the_DT parent_NN enzyme_NN upon_IN subsequent_JJ immunizations_NNS ._.
        It_PRP was_VBD of_IN interest_NN that_IN the_DT unmodified_JJ protease_NN induces_VBZ
        antigen-specific_JJ IgG_NNP in_IN the_DT absence_NN of_IN detectable_JJ
        immunodominant_NN T_NN cell_NN epitopes_NNS ._. BPN_NNP '_POS Y_NNP 217_CD L_NNP may_MD possess_VB weak_JJ
        T_NN cell_NN epitopes_NNS that_WDT are_VBP below_IN our_PRP$ limit_NN of_IN detection_NN in_IN
        our_PRP$ cell_NN culture_NN assay_NN ._. Our_PRP$ criterion_NN for_IN an_DT epitope_NN was_VBD an_DT
        average_JJ stimulation_NN index_NN of_IN 3_CD ._. 0_CD ._. In_IN addition_NN ,_, it_PRP is_VBZ
        notable_JJ that_IN both_DT of_IN the_DT immunogens_NNS tested_VBD display_NN
        considerable_JJ proteolytic_JJ activity_NN ._. The_DT proteolytic_JJ activity_NN
        of_IN the_DT parent_NN enzyme_NN could_MD be_VB responsible_JJ for_IN inducing_VBG T_NN
        cell_NN independent_JJ B_NNP cell_NN differentiation_NN via_IN a_DT number_NN of_IN
        different_JJ mechanisms_NNS [_NN 33_CD 34_CD 35_CD ]_NN ._. Finally_RB ,_, we_PRP have_VBP seen_VBN
        than_IN both_DT chemically_RB inactivated_JJ and_CC an_DT inactive_JJ variant_NN of_IN
        the_DT parent_NN protease_NN used_VBN in_IN these_DT experiments_NNS are_VBP incapable_JJ
        of_IN inducing_VBG IgG_NNP 1_CD in_IN a_DT mouse_NN model_NN (_( data_NNS not_RB shown_VBN )_) ._. The_DT
        proteolytic_JJ activity_NN of_IN these_DT molecules_NNS also_RB acts_VBZ as_IN an_DT
        adjuvant_NN for_IN specific_JJ IgG_NNP production_NN [_NN 36_CD ]_NN ._.
        The_DT ability_NN to_TO induce_VB improved_VBN immune_JJ responses_NNS by_IN the_DT
        subtle_JJ changes_NNS described_VBD here_RB could_MD have_VB a_DT number_NN of_IN
        potentially_RB vital_JJ applications_NNS ._. The_DT use_NN of_IN a_DT T_NN cell_NN
        epitope-modified_JJ whole_JJ protein_NN immunogen_NN confers_VBZ a_DT number_NN
        of_IN advantages_NNS ._. The_DT first_JJ advantage_NN is_VBZ the_DT priming_VBG of_IN a_DT
        diverse_JJ immune_JJ response_NN to_TO the_DT protein_NN that_WDT allows_VBZ the_DT
        generation_NN of_IN both_DT a_DT complex_JJ and_CC robust_JJ T_NN helper_NN responses_NNS ,_,
        and_CC secondly_RB the_DT concomitant_NN affinity_NN maturation_NN of_IN the_DT
        antibody_NN response_NN to_TO naturally_RB occurring_VBG antibody_NN epitopes_NNS ._.
        This_DT is_VBZ especially_RB relevant_JJ to_TO the_DT design_NN of_IN subunit_NN
        vaccines_NNS for_IN malaria_NN and_CC schistosomiasis_NNS where_WRB high_JJ titers_NNS
        of_IN high_JJ affinity_NN antibodies_NNS are_VBP usually_RB the_DT best_JJS defence_NN
        against_IN invading_VBG organisms_NNS [_NN 11_CD 16_CD 24_CD ]_NN ._. Creating_NNP T_NN cell_NN
        epitopes_NNS in_IN expressed_VBD proteins_NNS has_VBZ been_VBN demonstrated_VBN here_RB
        for_IN Hartley_NNP strain_NN guinea_NN pigs_NNS ,_, and_CC for_IN various_JJ inbred_JJ
        strains_NNS of_IN mice_NNS [_NN 37_CD 38_CD ]_NN ._. Interestingly_RB ,_, the_DT introduction_NN
        of_IN T_NN cell_NN epitopes_NNS from_IN a_DT hen-egg_JJ lysozyme_NN or_CC ovalbumin_NN
        into_IN mouse_NN TNF-alpha_NNP also_RB resulted_VBD in_IN an_DT increased_VBN
        cross-reactive_JJ antibody_NN response_NN in_IN mice_NNS [_NN 38_CD ]_NN ._. However_RB ,_,
        the_DT protein_NN construct_VB was_VBD no_DT longer_RB cytotoxic_JJ for_IN L_NNP 929_CD
        cells_NNS ,_, suggesting_VBG that_IN the_DT modified_VBN protein_NN was_VBD not_RB in_IN the_DT
        correct_JJ tertiary_JJ configuration_NN ._. Incorrect_NNP tertiary_JJ
        configuration_NN could_MD lead_VB to_TO the_DT production_NN of_IN specific_JJ
        antibodies_NNS that_WDT do_VBP not_RB cross-react_JJ with_IN the_DT native_JJ
        molecule_NN ._. T_NN cell_NN responses_NNS to_TO the_DT variants_NNS were_VBD not_RB well_RB
        characterized_VBN ._. In_IN this_DT paper_NN ,_, and_CC in_IN the_DT report_NN from_IN
        Tsujihata_NNP [_NN 37_CD ]_NN T_NN cell_NN epitopes_NNS were_VBD created_VBN within_IN the_DT
        molecule_NN of_IN interest_NN ,_, without_IN affecting_VBG the_DT activity_NN of_IN the_DT
        enzyme_NN ._. We_PRP created_VBD a_DT naturally_RB occurring_VBG T_NN cell_NN epitope_NN by_IN
        comparison_NN to_TO a_DT related_VBN protein_NN ._. In_IN addition_NN ,_, we_PRP found_VBD that_IN
        the_DT creation_NN of_IN a_DT T_NN cell_NN epitope_NN in_IN BPN_NNP '_POS Y_NNP 217_CD L_NNP resulted_VBD in_IN
        a_DT complex_JJ pattern_NN of_IN T_NN cell_NN response_NN to_TO the_DT enzyme_NN ._. The_DT
        challenge_NN of_IN utilizing_VBG this_DT technique_NN for_IN the_DT creation_NN of_IN
        subunit_NN vaccines_NNS for_IN the_DT human_JJ population_NN will_MD be_VB to_TO create_VB
        T_NN cell_NN epitopes_NNS within_IN a_DT protein_NN of_IN interest_NN that_WDT will_MD not_RB
        have_VB deleterious_JJ effects_NNS on_IN the_DT activity_NN or_CC the_DT stability_NN
        of_IN the_DT protein_NN of_IN interest_NN ,_, and_CC that_DT would_MD be_VB effective_JJ
        across_IN a_DT number_NN of_IN HLA-DR_NNP haplotypes_NNS [_NN 39_CD ]_NN ._.
        The_DT improved_VBN antibody_NN response_NN measured_VBN in_IN this_DT paper_NN
        was_VBD increased_VBN titers_NNS of_IN guinea_NN pig_NN polyclonal_NN IgG_NNP ._. We_PRP did_VBD
        not_RB measure_VB potential_JJ differences_NNS in_IN guinea_NN pig_NN IgG_NNP
        isotypes_NNS ._. Changing_VBG the_DT interaction_NN of_IN peptide_NN ,_, MHC_NNP class_NN II_NNP
        molecules_NNS ,_, T_NN cell_NN receptors_NNS and_CC other_JJ antigen-presenting_JJ
        cell_NN specific_JJ ligand_NN interactions_NNS to_TO foster_VB stronger_JJR ,_,
        higher_JJR affinity_NN T_NN cell_NN signalling_VBG has_VBZ been_VBN shown_VBN in_IN mice_NNS to_TO
        skew_NN T_NN cell_NN differentiation_NN from_IN Th_NNP 2_CD to_TO Th_NNP 1_CD -_: like_IN patterns_NNS [_NN
        40_CD 41_CD 42_CD 43_CD 44_CD 45_CD 46_CD 47_CD 48_CD 49_CD 50_CD ]_NN ._. Differences_NNS in_IN
        Th-differentiation_NNP patterns_NNS have_VBP downstream_JJ effects_NNS on_IN the_DT
        type_NN of_IN immune_JJ response_NN mounted_VBD ,_, and_CC in_IN particular_JJ on_IN the_DT
        isotypes_NNS of_IN antibody_NN expressed_VBD ._. This_DT has_VBZ been_VBN well_RB
        documented_VBN for_IN mice_NNS and_CC humans_NNS ,_, but_CC less_JJR is_VBZ known_VBN about_IN Th_NNP
        differentiation_NN in_IN Hartley_NNP strain_NN guinea_NN pigs_NNS ._.
        In_IN our_PRP$ system_NN ,_, we_PRP cannot_NN distinguish_VB if_IN the_DT amino_JJ acid_NN
        change_NN we_PRP have_VBP created_VBN has_VBZ its_PRP$ effects_NNS on_IN binding_VBG to_TO the_DT
        guinea_NN pig_NN MHC_NNP ,_, interaction_NN with_IN the_DT T_NN cell_NN receptor_NN ,_, or_CC
        more_RBR efficient_JJ processing_NN of_IN the_DT epitope_NN from_IN the_DT protein_NN
        precursor_NN [_NN 51_CD ]_NN ._. Any_DT or_CC all_DT of_IN these_DT mechanisms_NNS could_MD
        contribute_VB to_TO the_DT enrichment_NN for_IN peptide-specific_JJ
        proliferative_JJ responses_NNS seen_VBN in_IN vitro_NN ._.
        The_DT ability_NN to_TO up_RB regulate_VB antibody_NN and_CC T_NN cell_NN responses_NNS
        to_TO whole_JJ protein_NN immunogens_NNS by_IN the_DT modification_NN of_IN T_NN cell_NN
        epitopes_NNS suggests_VBZ that_IN the_DT converse_NN would_MD also_RB be_VB possible_JJ ._.
        Down_IN regulation_NN of_IN T_NN cell_NN responses_NNS to_TO functionally_RB intact_JJ
        enzymes_NNS would_MD have_VB obvious_JJ implications_NNS for_IN both_DT existing_VBG
        and_CC potential_JJ protein_NN therapeutics_NNS ._.
      
      
        Conclusions_NNP
        The_DT immunogenicity_NN of_IN an_DT enzyme_NN can_MD be_VB increased_VBN ,_, while_IN
        maintaining_VBG the_DT majority_NN of_IN its_PRP$ stability_NN and_CC proteolytic_JJ
        activity_NN ,_, by_IN incorporating_VBG a_DT single_JJ amino_JJ acid_NN change_NN ._. The_DT
        variant_NN enzyme_NN was_VBD found_VBN to_TO have_VB a_DT major_JJ T_NN cell_NN epitope_NN
        where_WRB none_NN existed_VBD in_IN the_DT parent_NN ._. In_IN addition_NN to_TO the_DT
        increased_VBN cellular_JJ response_NN ,_, humoral_NN responses_NNS were_VBD
        increased_VBN at_IN low_JJ doses_NNS ,_, and_CC as_RB well_RB for_IN high_JJ doses_NNS early_RB in_IN
        the_DT immunization_NN schedule_NN ._. Enhancing_NNP the_DT T_NN cell_NN response_NN to_TO
        an_DT enzyme_NN ,_, in_IN addition_NN to_TO the_DT humoral_NN response_NN ,_, has_VBZ
        applications_NNS in_IN the_DT construction_NN of_IN recombinant_JJ vaccines_NNS as_RB
        well_RB as_IN in_IN protein-based_JJ therapeutics_NNS ._.
      
      
        Materials_NNS and_CC Methods_NNP
        
          Protease_NNP enzymes_NNS
          GP_NNP 002_CD was_VBD created_VBN by_IN site-directed_JJ mutagenesis_NNS of_IN the_DT
          sequence_NN of_IN BPN_NNP '_POS Y_NNP 217_CD L_NNP and_CC expressed_VBD in_IN 
          B_NNP ._. subtilisn_NN ._. Enzymes_NNP were_VBD purified_JJ
          from_IN fermentation_NN broths_NNS utilizing_VBG the_DT BioCAD_NNP 700_CD E_NNP system_NN
          (_( Perceptive_NNP Biosystems_NNP ,_, Foster_NNP City_NNP ,_, CA_NNP )_) using_VBG POROS_NNP HS_NNP /_NN M_NNP
          resin_NN (_( Perceptive_NNP Biosystems_NNP ,_, Foster_NNP City_NNP ,_, CA_NNP )_) on_IN porous_JJ
          polystyrene_NN beads_NNS ,_, and_CC was_VBD stored_VBN as_IN stock_NN solutions_NNS at_IN
          20_CD mg_NN /_NN ml_NN in_IN 20_CD mM_NN MES_NNP ,_, pH_NN 5_CD ._. 5_CD with_IN 1_CD mM_NN CaCL_NNP 
          2_CD at_IN -_: 20_CD °_NN C_NNP ._.
        
        
          Enzyme_NNP activity_NN and_CC stability_NN measurements_NNS
          Proteolytic_NNP activity_NN was_VBD measured_VBN by_IN hydrolysis_NNS of_IN the_DT
          substrate_NN succinyl-_NN AAPF-p-nitroanilide_NNP (_( suc-_NN AAPF-pNA_NNP )_) ._.
          Serial_JJ dilutions_NNS of_IN the_DT proteases_NNS were_VBD made_VBN in_IN 100_CD mM_NN
          Tris_NNP buffer_NN ,_, pH_NN 8_CD ._. 6_CD ,_, containing_VBG 10_CD mM_NN CaCl_NNP 
          2_CD ._. Enzyme_NNP activity_NN was_VBD measured_VBN at_IN
          25_CD °_NN C_NNP in_IN 100_CD mM_NN Tris_NNP /_NN HCl_NNP ,_, pH_NN 8_CD ._. 6_CD containing_VBG 1_CD ._. 6_CD mM_NN
          suc-_NN AAPF-pNA_NNP (_( Bachem_NNP Bioscience_NNP ,_, Torrance_NNP ,_, CA_NNP )_) ,_, 0_CD ._. 0005_CD %_NN
          Tween-_NNP 80_CD and_CC 1_CD %_NN DMSO_NNP by_IN monitoring_VBG the_DT absorbance_NN change_NN
          at_IN 410_CD nm_NN using_VBG a_DT spectrophotometer_NN ._. Each_DT dilution_NN of_IN
          enzyme_NN was_VBD tested_VBN in_IN triplicate_NN ._. Three_CD dilutions_NNS were_VBD
          tested_VBN for_IN each_DT enzyme_NN ._. Activity_NN was_VBD then_RB determined_VBN by_IN
          linear_JJ regression_NN ,_, and_CC is_VBZ reported_VBN as_IN OD_NNP units_NNS /_NN mg_NN
          enzyme_NN ._.
          Comparative_NNP thermostability_NN was_VBD determined_VBN for_IN BPN_NNP '_POS
          Y_NNP 217_CD L_NNP and_CC GP_NNP 002_CD by_IN incubating_VBG the_DT enzymes_NNS (_( 0_CD ._. 5_LS ppm_NN )_) at_IN
          37_CD °_NN C_NNP in_IN 50_CD mM_NN TES_NNP buffer_NN ,_, pH_NN 7_CD ._. 3_CD containing_VBG 0_CD ._. 0005_CD %_NN
          Tween-_NNP 80_CD ._. Aliquots_NNP of_IN the_DT enzyme_NN solutions_NNS were_VBD removed_VBN
          over_IN time_NN ,_, diluted_VBN and_CC assayed_JJ for_IN activity_NN using_VBG 1_CD mM_NN
          suc-_NN AAPF-pNA_NNP substrate_NN in_IN 100_CD mM_NN Tris_NNP pH_NN 8_CD ._. 6_CD containing_VBG
          0_CD ._. 0005_CD %_NN Tween-_NNP 80_CD ._. The_DT half-lives_JJ of_IN the_DT enzymes_NNS were_VBD then_RB
          calculated_VBN using_VBG a_DT linear_JJ regression_NN ._.
        
        
          Immunization_NNP protocols_NNS
          
            1_LS ._. BPN_NNP '_POS Y_NNP 217_CD L_NNP ,_, B_NNP ._. lentus_JJ subtilisin_NN ,_, and_CC GP_NNP 002_CD
            immunizations_NNS
            Guinea_NNP pig_NN immunizations_NNS were_VBD outsourced_JJ to_TO EL_NNP Labs_NNPS
            in_IN Santa_NNP Cruz_NNP ,_, CA_NNP ._. Female_NNP Hartley_NNP outbred_JJ guinea_NN pigs_NNS
            weighing_VBG 200_CD -_: 600_CD grams_NNS were_VBD used_VBN in_IN all_DT studies_NNS ._. There_EX
            were_VBD three_CD or_CC four_CD dosages_NNS of_IN the_DT appropriate_JJ enzyme_NN
            and_CC for_IN each_DT dosage_NN there_EX were_VBD four_CD animals_NNS immunized_JJ ._.
            Each_DT group_NN of_IN four_CD animals_NNS was_VBD immunized_JJ every_DT two_CD
            weeks_NNS ,_, immediately_RB after_IN the_DT removal_NN of_IN a_DT serum_NN sample_NN ._.
            There_EX were_VBD a_DT total_NN of_IN six_CD immunizations_NNS ._. The_DT first_JJ
            immunization_NN was_VBD in_IN Complete_JJ Freund_NNP 's_POS Adjuvant_NNP ._.
            Incomplete_NNP Freund_NNP 's_POS Adjuvant_NNP was_VBD used_VBN for_IN all_DT
            subsequent_JJ immunizations_NNS ._. Each_DT immunogen_NN was_VBD provided_VBN
            as_IN a_DT stock_NN solution_NN at_IN 20_CD mg_NN /_NN ml_NN in_IN 20_CD mM_NN sodium_NN
            acetate_NN ,_, 1_CD mM_NN calcium_NN chloride_NN ,_, and_CC was_VBD diluted_VBN to_TO
            1_CD ,_, 5_CD ,_, 10_CD ,_, or_CC 20_CD μg_NN /_NN ml_NN in_IN cold_JJ DPBS_NNP to_TO a_DT total_JJ volume_NN of_IN 1_CD
            ml_NN ._. This_DT was_VBD emulsified_JJ at_IN a_DT 1_CD :_: 1_CD ratio_NN with_IN CFA_NNP or_CC IFA_NNP ._.
            Each_DT guinea_NN pig_NN was_VBD immunized_JJ subcutaneously_RB with_IN a_DT
            total_NN of_IN 500_CD μl_NN of_IN emulsion_NN ._.
          
          
            2_LS ._. Priming_NNP study_NN with_IN BPN_NNP '_POS Y_NNP 217_CD L_NNP and_CC GP_NNP 002_CD
            Guinea_NNP pig_NN immunizations_NNS were_VBD out-sourced_JJ to_TO EL_NNP Labs_NNPS
            in_IN Santa_NNP Cruz_NNP ,_, CA_NNP ._. The_DT following_VBG immunization_NN protocol_NN
            was_VBD followed_VBN :_: four_CD groups_NNS of_IN four_CD Hartley_NNP guinea_NN pigs_NNS
            were_VBD distinguished_VBN as_IN groups_NNS A_DT through_IN D_NNP ._. All_DT animals_NNS
            received_VBD 5_CD μg_NN of_IN immunogen_NN ._. The_DT first_JJ immunization_NN was_VBD
            performed_VBN in_IN CFA_NNP ,_, then_RB IFA_NNP for_IN all_DT subsequent_JJ
            immunizations_NNS ._. Each_DT animal_NN received_VBD a_DT total_NN of_IN 500_CD μl_NN
            of_IN emulsion_NN ._. All_DT immunizations_NNS were_VBD performed_VBN
            subcutaneously_RB using_VBG the_DT following_JJ schedule_NN :_: First_CD
            immunization_NN -_: Group_NNP A_DT received_VBD BPN_NNP '_POS Y_NNP 217_CD L_NNP ,_, groups_NNS B-D_NNP
            GP_NNP 002_CD ._. Week_NNP two_CD -_: Groups_NNS A_DT and_CC B_NNP received_VBD BPN_NNP '_POS Y_NNP 217_CD L_NNP ,_,
            Groups_NNS B_NNP and_CC C_NNP received_VBD GP_NNP 002_CD ._. Week_NNP 4_CD -_: Groups_NNS A_DT
            through_IN C_NNP received_VBD BPN_NNP '_POS Y_NNP 217_CD L_NNP ,_, Group_NNP D_NNP received_VBD GP_NNP 002_CD ._.
            Serum_NNP samples_NNS were_VBD drawn_VBN at_IN week_NN 6_CD ._.
          
          
            3_LS ._. T-_NNP cell_NN epitope_NN mapping_NN for_IN GP_NNP 002_CD and_CC BPN_NNP '_POS
            Y_NNP 217_CD L_NNP
            Guinea_NNP pig_NN immunizations_NNS were_VBD outsourced_JJ to_TO
            Strategic_NNP BioSolutions_NNP ,_, Ramona_NNP ,_, CA_NNP ._. Groups_NNS of_IN 10_CD female_JJ
            Hartley_NNP strain_NN guinea_NN pigs_NNS were_VBD immunized_JJ every_DT two_CD
            weeks_NNS with_IN 5_CD ug_NN per_IN dose_NN of_IN BPN_NNP '_POS Y_NNP 217_CD L_NNP or_CC GP_NNP 002_CD in_IN
            Complete_JJ Freund_NNP 's_POS adjuvant_NN ,_, then_RB Incomplete_NNP Freund_NNP 's_POS as_IN
            described_VBN above_IN ._. Two_CD weeks_NNS following_VBG the_DT third_JJ
            immunization_NN ,_, animals_NNS were_VBD sacrificed_JJ and_CC their_PRP$ spleens_NNS
            and_CC serum_NN samples_NNS collected_VBN ._.
          
        
        
          ELISA_NNP protocols_NNS (_( whole_JJ protein_NN IgG_NNP )_)
          Medium_NNP binding_JJ EIA_NNP plates_NNS (_( Costar_NNP ,_, Cambridge_NNP ,_, MA_NNP )_) were_VBD
          coated_VBN with_IN 10_CD μg_NN /_NN ml_NN of_IN acid-denatured_JJ enzyme_NN in_IN DPBS_NNP ._.
          Enzyme_NNP was_VBD coated_JJ onto_IN the_DT plates_NNS at_IN 4_CD °_NN C_NNP overnight_JJ ._.
          Plates_NNP were_VBD then_RB washed_VBN three_CD times_NNS with_IN PBS_NNP /_NN 0_CD ._. 25_CD %_NN
          Tween-_NNP 20_CD (_( Sigma_NNP ,_, St_NNP ._. Louis_NNP ,_, MO_NNP )_) ._. Plates_NNP were_VBD blocked_VBN with_IN
          1_CD %_NN BSA_NNP (_( Rockland_NNP ,_, Gilbertsville_NNP ,_, PA_NNP )_) /_NN PBS_NNP at_IN room_NN
          temperature_NN for_IN 30_CD minutes_NNS ._. Ten-fold_NNP serial_NN dilution_NN of_IN
          sera_NN in_IN 1_CD %_NN BSA_NNP /_NN PBS_NNP were_VBD performed_VBN ._. The_DT plates_NNS were_VBD
          covered_VBN and_CC incubated_JJ at_IN room_NN temperature_NN for_IN two_CD hours_NNS ._.
          Secondary_JJ biotin_NN anti-_NN IgG_NNP antibody_NN (_( guinea_NN pig_NN IgG_NNP Fc_NNP
          specific_NN ,_, Jackson_NNP ImmunoResearch_NNP ,_, West_NNP Grove_NNP ,_, PA_NNP )_) was_VBD
          diluted_VBN 1_CD :_: 10_CD ,_, 000_CD in_IN 1_CD %_NN BSA_NNP /_NN PBS_NNP ._. 100_CD μl_NN of_IN this_DT dilution_NN
          were_VBD placed_VBN per_IN well_RB on_IN the_DT plates_NNS ._. The_DT plates_NNS were_VBD again_RB
          covered_VBN and_CC incubated_JJ at_IN room_NN temperature_NN for_IN 1_CD hour_NN ._.
          Plates_NNP were_VBD washed_VBN (_( as_IN above_IN )_) ._. Avidin-_NNP HRP_NNP (_( Jackson_NNP
          ImmunoResearch_NNP )_) was_VBD diluted_VBN 1_CD :_: 1000_CD in_IN 1_CD %_NN BSA_NNP /_NN PBS_NNP and_CC 100_CD
          μl_NN per_IN well_RB were_VBD added_VBN to_TO the_DT plates_NNS ._. Plates_NNP were_VBD covered_VBN
          and_CC incubated_JJ at_IN room_NN temperature_NN for_IN 30_CD minutes_NNS ._. The_DT
          plates_NNS were_VBD washed_VBN (_( as_IN above_IN )_) ._. The_DT ELISAs_NNP were_VBD developed_VBN
          with_IN ABTS_NNP in_IN citrate_NN buffer_NN with_IN 0_CD ._. 03_CD %_NN H_NNP 2_CD O_NNP 2_CD ,_, at_IN room_NN
          temperature_NN for_IN 40_CD minutes_NNS and_CC then_RB read_VB at_IN OD_NNP =_SYM 405_CD nm_NN ._.
          Titers_NNP were_VBD found_VBN by_IN using_VBG a_DT log-based_JJ slope_NN equation_NN
          where_WRB the_DT O_NNP ._. D_NNP ._. =_SYM 0_CD ._. 5_CD ._.
        
        
          Peptides_NNP
          1_LS ._. Proliferation_NNP assays_NNS :_: 15_CD -_: mer_NN peptides_NNS offset_VBN by_IN 3_CD
          amino_JJ acids_NNS describing_VBG the_DT proteins_NNS of_IN interest_NN were_VBD
          obtained_VBN as_IN a_DT Pep_NNP Set_NNP from_IN Mimotopes_NNP (_( San_NNP Diego_NNP ,_, CA_NNP )_) ._. Pep_NNP
          Sets_NNP were_VBD constructed_VBN for_IN 
          Bacillus_NN lentus_JJ subtilisin_NN (_( 
          B_NNP ._. lentus_JJ subtilisin_NN )_) and_CC 
          Bacillus_NN
          amyloliqufaciens_NNS subtilisin_NN (_( subtilisin_NN BPN_NNP '_POS Y_NNP 217_CD L_NNP )_) ._.
          Peptides_NNP were_VBD resuspended_JJ in_IN DMSO_NNP at_IN 1_CD mM_NN ._.
          2_LS ._. Linear_NNP epitopes_NNS :_: Biotinylated_NNP 15_CD -_: mer_NN peptides_NNS from_IN
          obtained_VBN from_IN Mimotopes_NNP (_( San_NNP Diego_NNP ,_, CA_NNP )_) ._. The_DT 15_CD -_: mer_NN
          peptides_NNS were_VBD offset_VBN by_IN 5_CD amino_JJ acids_NNS ,_, and_CC described_VBD the_DT
          sequence_NN of_IN BPN_NNP '_POS Y_NNP 217_CD L_NNP ._. The_DT biotin_NN moiety_NN at_IN the_DT
          N-_NNP terminus_JJ was_VBD separated_JJ from_IN the_DT peptide_NN sequence_NN of_IN
          interest_NN by_IN a_DT 4_CD amino_JJ acid_NN spacer_NN ._. Biotinylated_NNP peptides_NNS
          were_VBD resuspended_JJ at_IN 1_CD mM_NN in_IN DMSO_NNP ._.
        
        
          T-_NNP cell_NN epitope_NN mapping_NN of_IN enzymes_NNS B_NNP ._. lentus_JJ
          subtilisin_NN ,_, BPN_NNP '_POS Y_NNP 217_CD L_NNP and_CC GP_NNP 002_CD
          T_NN cell_NN epitope_NN mapping_NN was_VBD performed_VBN using_VBG splenocytes_NNS
          from_IN immunized_JJ Hartley_NNP strain_NN guinea_NN pigs_NNS ._. Splenocytes_NNP
          from_IN immunized_JJ guinea_NN pigs_NNS were_VBD resuspended_JJ in_IN AIM-V_NNP
          (_( Life_NNP Technologies_NNPS Gaithersberg_NNP ,_, MD_NNP )_) containing_VBG 100_CD
          units_NNS /_NN ml_NN penicillin_NN ,_, 100_CD ug_NN /_NN ml_NN streptomycin_NN ,_, 1_CD mM_NN
          glutamine_NN ,_, and_CC either_CC 10_CD %_NN autologous_JJ serum_NN or_CC 10_CD %_NN FCS_NNP
          (_( Sigma_NNP ,_, St_NNP ._. Louis_NNP ,_, MO_NNP )_) ._. Using_VBG round-bottom_JJ 96_CD well_RB plates_NNS
          (_( Costar_NNP ,_, Cambridge_NNP ,_, MA_NNP )_) ,_, either_CC 5_CD ×_NN 10_CD 5_CD or_CC 1_CD ×_NN 10_CD
          6_CD cells_NNS /_NN well_RB in_IN 200_CD uL_NN of_IN media_NNS ._. 5_LS uM_NN of_IN peptide_NN were_VBD
          placed_VBN in_IN each_DT well_RB ._. Each_DT peptide_NN was_VBD tested_VBN minimally_RB in_IN
          duplicate_VB ._. DMSO_NNP was_VBD present_JJ at_IN 0_CD ._. 5_CD %_NN ._. Control_NN cultures_NNS
          contained_VBD 0_CD ._. 5_CD %_NN DMSO_NNP in_IN the_DT absence_NN of_IN peptide_NN ._. The_DT
          cultures_NNS were_VBD incubated_JJ at_IN 37_CD °_NN C_NNP for_IN 5_CD days_NNS ._. On_IN day_NN 5_CD ,_,
          cells_NNS were_VBD pulsed_JJ with_IN tritiated_JJ thymidine_NN at_IN a_DT
          concentration_NN of_IN 0_CD ._. 5_CD μCi_NN /_NN well_RB ._. On_IN day_NN 6_CD ,_, cells_NNS were_VBD
          harvested_VBN and_CC counted_VBN ._. A_DT proliferative_JJ response_NN was_VBD
          counted_VBN as_IN positive_JJ if_IN the_DT average_JJ counts_NNS for_IN a_DT
          particular_JJ peptide_NN were_VBD three_CD times_NNS higher_JJR than_IN the_DT
          control_NN levels_NNS ._.
        
        
          Linear_NNP B-_NNP cell_NN epitope_NN mapping_NN of_IN enzymes_NNS BPN_NNP '_POS Y_NNP 217_CD L_NNP
          and_CC GP_NNP 002_CD
          Biotinylated_NNP peptides_NNS were_VBD resuspended_JJ in_IN 1_CD ml_NN of_IN DMSO_NNP
          (_( 1_CD mM_NN )_) ._. A_DT stock_NN plate_NN was_VBD made_VBN by_IN diluting_VBG 10_CD μl_NN of_IN each_DT
          peptide_NN into_IN 200_CD μl_NN of_IN PBS_NNP /_NN 0_CD ._. 025_CD %_NN Tween-_NNP 20_CD (_( Sigma_NNP ,_, St_NNP ._.
          Louis_NNP ,_, MO_NNP )_) ._. Streptavidin-coated_NNP plates_NNS (_( Pierce_NNP ,_, Rockford_NNP ,_,
          IL_NNP )_) were_VBD blocked_VBN with_IN 1_CD %_NN BSA_NNP /_NN PBS_NNP for_IN 30_CD minutes_NNS at_IN room_NN
          temperature_NN ._. Approximately_RB 5_CD μM_NN of_IN biotinylated_JJ peptide_NN
          was_VBD coated_JJ onto_IN each_DT well_RB ._. Each_DT peptide_NN was_VBD tested_VBN
          minimally_RB in_IN duplicate_VB ._. Plates_NNP were_VBD incubated_JJ for_IN one_CD
          hour_NN at_IN room_NN temperature_NN and_CC then_RB washed_VBN three_CD times_NNS ._.
          Guinea_NNP pig_NN serum_NN was_VBD diluted_VBN 1_CD :_: 1000_CD in_IN PBS_NNP /_NN Tween-_NNP 20_CD ._. 100_CD
          μl_NN of_IN dilute_VB sera_NN was_VBD placed_VBN into_IN each_DT well_RB and_CC plates_NNS
          were_VBD incubated_JJ at_IN room_NN temperature_NN for_IN one_CD hour_NN and_CC then_RB
          washed_VBN three_CD times_NNS ._. The_DT secondary_JJ antibody_NN ,_, anti-guinea_JJ
          pig_NN IgG-HRPO_NNP )_) (_( Jackson_NNP ImmunoResearch_NNP ,_, West_NNP Grove_NNP ,_, PA_NNP )_)
          was_VBD diluted_VBN 1_CD :_: 1000_CD in_IN 1_CD %_NN BSA_NNP /_NN PBS_NNP and_CC 100_CD μl_NN of_IN dilute_VB
          conjugate_NN was_VBD added_VBN to_TO each_DT well_RB ._. Plates_NNP were_VBD incubated_JJ
          at_IN room_NN temperature_NN for_IN 1_CD hour_NN and_CC then_RB washed_VBN three_CD
          times_NNS in_IN PBS_NNP /_NN Tween-_NNP 20_CD ._. Plates_NNP were_VBD then_RB washed_VBN twice_RB in_IN
          PBS_NNP only_RB ._. ELISAs_NNP were_VBD developed_VBN using_VBG ABTS_NNP in_IN citrate_NN
          buffer_NN ,_, 0_CD ._. 03_CD %_NN H_NNP 2_CD O_NNP 2_CD ._. Plates_NNP were_VBD then_RB incubated_JJ at_IN room_NN
          temperature_NN for_IN up_IN to_TO 45_CD minutes_NNS and_CC then_RB read_VB at_IN 405_CD nm_NN ._.
          OD_NNP readings_NNS for_IN each_DT peptide_NN were_VBD compared_VBN to_TO background_NN
          readings_NNS with_IN no_DT peptide_NN ._. Any_DT peptide_NN giving_VBG readings_NNS at_IN
          least_JJS twice_RB the_DT background_NN was_VBD considered_VBN a_DT positive_NN ._.
        
      
    
  
